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Abstract 
Background: Obesity is a complex disorder and has been increasing globally at alarming rates including Pakistan. 
However, there is scarce research on understanding obesity genetics in Pakistan. Leptin is a hormone secreted by 
adipocytes in response to satiety and correlates with body weight. Any mutations in the LEP gene have an adverse 
effect on energy regulation pathway and lead to severe, early onset obesity. To date, only eight mutations have been 
described in the LEP gene of which p. N103K is one.
Methods: We aimed to analyze the prevalence of this mutation in Pakistani subjects. A total of 475 subjects were 
genotyped by PCR–RFLP analysis and their serum profiling was done.
Results: Results showed that this mutation was present only in one male child with early onset obesity (10 year). He 
had very low serum leptin levels suggestive of functional impact of the mutation. The prevalence of such mutations 
is, however, low due to the drastic effects on the energy regulation.
Conclusion: In conclusion, LEP gene mutations contribute significantly to the monogenic forms of obesity and are 
important due to the availability of treatment options. Such mutations may exert their effect by directly affecting 
energy regulation pathway and are more prominent in the early stages of life only.
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Background
Obesity is defined as a medical condition in which excess 
body fat accumulation can impact health negatively. It has 
become one of the leading disorders afflicting mankind 
worldwide. Due to recent explosion of the obesity World 
Health Organization (WHO) has designated obesity a 
global epidemic. Obesity is a heterogeneous disorder 
involving a complex interaction of multitude of including 
environmental, behavioural and genetic factors, none of 
which are completely understood [1]. Genetic studies on 
obesity started as a result of the observation that family 
clustering occurs in obesity. A landmark discovery in the 
field of obesity genetics was the identification of muta-
tions in the leptin gene in grossly obese children followed 
by identification of mutations in other genes involved 
in energy regulation pathways laying down the basis for 
monogenic obesity [2].
Leptin is a protein secreted by adipocytes, the fat cells, 
and its concentration in blood positively correlates with 
body fat mass and body mass index (BMI). It has a dis-
tinct impact on various physiological processes including 
energy metabolism, endocrine and immune systems [3]. 
It controls body fat by inhibiting food intake due to tar-
geting central nervous system. In addition to controlling 
body fat, leptin also has important funtions in reproduc-
tive organs, mammary glands, immune system and bone 
mineral density [4]. Leptin hormone is a member of long 
chain helical cytokines’ family, the other members of the 
family are important regulators e.g., interleukin-6, granu-
locyte colony-stimulating factor and growth hormone 
[5]. The hormone is a synthesized as 167 amino acid pro-
tein which is immature. The processing involves cleavage 
of a 21-amino acid N-terminal signal sequence produc-
ing a mature functional non glycosylated 146-amino acid 
protein [6]. LEP gene is present on 7q31.3 chromosomal 
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region and includes three exons intervened by two 
introns [7]. The gene was identified in 1994 by positional 
cloning and is ~16 kb long [6]. Only eight mutations have 
been identified in LEP gene at the present causing severe 
early onset obesity [4, 8–17]. We selected g.13285C>A 
missense mutation originally reported in an obese Egyp-
tian child, to investigate whether this mutation is present 
in Pakistani population or is restricted to a particu-
lar ethnic group. This mutation leads to substitution of 
asparagine to lysine at position 103 (p. N103K) at protein 
level [4] causing a reduction of biological activity of the 
mutant protein and very low serum leptin levels [18].
Pakistan with a total population of 184.35 millions 
in 2012–2013 is the 6th  most populous country of the 
world. According to the Global Burden of Disease Study, 
in terms of obesity, it ranked 9th out of 188 countries 
[19]. Pakistan faced a lot of health challenges during a 
decade long war on terror [20]. LEP gene p. N103K muta-
tion has not been investigated in the Pakistani subjects 
previously. Keeping in view the global research per-
spective, limited research with regard to obesity and no 
research of the mutation in Pakistan, we aimed to find 
out whether this mutation plays any role in obesity in the 
Pakistani population and which serum parameters are 
affected by the mutation, if there are any.
Methods
Study subjects
The study was designed as a case control observational 
type. Subjects were recruited from January 2011 to June 
2014 from different areas of Punjab Pakistan. A total 
of 475 unrelated subjects was selected after obtaining 
informed consent and the subjects filled in a detailed 
questionnaire related to diet, lifestyle, disease and family 
history. The recruitmen, inclusion and exclusion criteria 
to define and differentiate different categories of subjects 
have been described elsewhere [21].
Ethics, consent and permissions
All procedures were in compliance of Helsinki Declara-
tion and the study was approved by the institutional eth-
ics committee (Ethical Committee, School of Biological 
Sciences, University of the Punjab, Pakistan).
Anthropometric traits’ measurement
Anthropometric traits including weight (Wt), height 
(Ht), waist and hip circumference (WC, HC), systolic and 
diastolic blood pressure (SBP, DBP) were measured as 
described previously [21].
Biochemical analyses
5  ml of blood was drawn by venipuncture from the 
median cubital vein after 8–12 h fasting, 2 ml was poured 
in a gel clot activator containing vacutainer that was 
centrifuged to separate plasma used for determination 
of biochemical parameters while 3 ml was poured in an 
EDTA containing vacutainer that prevented blood from 
clotting and was used for DNA isolation. Serum was 
screened for HBV, HCV and HIV. Positive samples were 
discarded and safe samples were proceeded. Serum fast-
ing plasma glucose (FPG), total cholesterol (TC), triglyc-
erides (TG), High Density and Low Density lipoprotein 
cholesterol (HDL-c, LDL-c), were determined using com-
mercially available kits (Spectrum Diagnostics, Egypt), 
leptin by LDN Nordhorn leptin ELISA kit whereas insu-
lin concentration was measured using electrochemilu-
minescence method as described previously [22], and 
HOMA-IR was calculated.
Genetic analysis
Genomic DNA was isolated from blood leukocytes by 
salting out method. The primers used for genotyping p. 
N103K mutation were described previously [23]. The 
sequence of the primers was forward: 5′-GCACTTGTT 
CTCCCTCTTCCT-3′ and reverse:, 5′-GTTCCTTCC 
CTTAACGTAGTCCT-3′ and were synthesized by Gene 
Link™, USA. PCR reaction conditions consisted of initial 
denaturation at 95 °C for 2 min, 35 cycles of denaturation 
at 95 °C for 35 s, annealing at 53 °C for 30 s, then exten-
sion at 72  °C for 30  s and a final extension at 72  °C for 
5  min. The 438  bp PCR product contains seven restric-
tion sites for MnlI in the wild type state. Presence of 
mutation leads to the loss of one of the seven restriction 
sites. 5 µl of the PCR product was used for digestion with 
MnlI (Thermo Fisher Scientific, USA). The digestion mix-
ture containing PCR product, enzyme and an appropriate 
enzyme buffer was incubated at 37 °C for 6 h.
Results
The characteristics of the study subjects included in the 
study have been described previously [21]. All param-
eters except height differed significantly between cases 
and controls as tested by independent sample t test. The 
FBG, systolic and diastolic blood pressure, leptin, insulin 
and HOMA-IR were significantly elevated in obese cases 
as compared to controls while the lipid profile was also 
dyslipidemic in the case group.
We could detect p. N103K mutation in homozygous 
state in only one subject (Figs. 1, 2). When the history of 
the subject was studied, it was a boy with age 10  years, 
early onset of obesity, hyperphagia, weighed 85  kg 
with height 85  cm (BMI  =  48.44  kg/m2), other siblings 
included two normal weight sisters and an overweight 
elder brother, parents were normal weight (BMI of mother 
was 23.9 kg/m2 and of father 26.5 kg/m2), the overweight 
brother and parents were found to be heterozygous for 
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the mutation while the child had p. N103K mutation in 
homozygous state. The family was a large, highly consan-
guineous one with multiple obese individuals (Fig. 3). The 
serum lipid profile and leptin levels of all study subjects 
were determined. Lipid profile of the propositus turned 
out to be in normal range, whereas leptin levels were close 
to the detection limit as measured by ELISA (0.1–1.0 ng/
ml). Although we obtained samples from proband and his 
parents, other obese relatives did not agree to give blood 
samples therefore the inheritance pattern of the mutation 
could not be established. In addition, limited information 
was available on the maternal family history of the child 
with more recall bias.
Discussion
In the current study, the prevalence of the p. N103K 
mutation in the coding region of the LEP gene was 
checked to demonstrate the role of LEP gene variations 
in the development of obesity in Pakistan. LEP gene is a 
known candidate gene, mutations in which contribute 
to severe early onset obesity due to the important physi-
ological roles leptin performs in circulation, by ultimately 
affecting hypothalamus. It is a known monogenic cause of 
obesity worldwide and all mutations in the gene reported 
so far result in severe disturbance of body weight regula-
tion (Table 1). 
Congenital leptin deficiency is a rare form of mono-
genic obesity and was first reported in two cousins of 
Pakistani origin with severe early onset obesity who had 
very low serum leptin levels. These two subjects were 
found to be homozygous for a frame shift mutation 
resulting in a misfolded protein which was not secreted 
[16]. A second mutation was identified in a Turkish fam-
ily with severe early onset obesity [15]. p. N103K was the 
third to be identified in an Egyptian child [23]. Five more 
mutations were discovered afterwards in the LEP gene. 
All of these known mutations with important points are 
summarized in Table 2.
The mutation p. N103K in exon 3 of LEP gene was 
shown to be invariably associated very strongly with 
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Fig. 2 Polyacrylamide gel electrophoresis of restriction digestion of amplified region for N103K, lane 1 is marker (25 bp DNA ladder SM#1191, 
Thermo Scientific), lanes 2 and 4 are heterozygous parents, lane 3 is homozygous proband, and lanes 5, 6 are controls. Presence of mutation abol-
ishes one of the seven restriction sites of MnlI
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serum leptin levels. The effect of this missense mutation 
involves a change of asparagine to lysine at position 103 
in the final protein resulting in very low serum leptin lev-
els as observed in the current study as well as the original 
report of two Egyptian patients [4]. Although the effect 
of this amino acid change on the synthesis, secretion and 
biological activity of leptin was not clearly demonstrated, 
the assessment of altered biological activity in vitro was 
checked in a study by Niv-Spector et  al. [29]. In this 
study, a prokaryotic expression system was used to pro-
duce p. N103K leptin and it was shown that this results 
in a drastic reduction in biological activity of the mutant 
leptin protein. This observation led to the hypothesis that 
defective biological activity in addition to already lower 
serum levels contributes to the severe obese phenotype 
seen in p. N103K patients.
Conclusion
In conclusion, the congenital leptin deficiency is very rare 
and the frequency of mutations reported in LEP gene 
is very low. However, the molecular diagnosis of these 
mutations is very important due to the availability of 
Fig. 3 Pedigree of the Propositus. I-1: Proband’s deceased maternal grandmother. I-2: Proband’s deceased maternal grandfather. I-3: Proband’s 
deceased paternal grandfather (reported as obese by proband’s father, genotype not available). I-4: Proband’s deceased paternal grandmother 
(reported as overweight by proband’s father, genotype not available). II-5: Proband’s normal weight mother (BMI: 23.9 kg/m2, genotype CA). II-6: 
Proband’s normal weight mother (BMI: 26.5 kg/m2, genotype CA). III-6, 7: Proband’s normal weight sisters (BMI < 22 kg/m2, genotype CC). III-8: 
Proband’s overweight elder brother (BMI: 27.2 kg/m2, genotype CA). III-9: Proband, age of onset: 10 (BMI: 48.44 kg/m2, genotype AA)
Table 1 Overview of Mutations reported in LEP gene
Name of mutation Nature of change Amino acid change Ethnicity Consanguinity No of subjects References
g. 13374delG Frameshift Gly-Val Pakistani Yes 2 Montague et al. [16]
g13289C>T Missense Arg-Trp Turkish Yes 3 Strobel et al. [15]
g. 13398C>G Missense Ser-Cys Turkmenian Unknown Unknown Chekhranova et al. [24]
g. 13285C>A Missense Asn-Lys Egyptian Yes 2 Mazen et al. [23]
g. 13191T>C Missense Leu-Ser Austrian Unknown 1 Funcke et al. [25]
g. 10839_10841delTCA Codon deletion del Isoleu Pakistani Yes 1 Saeed et al. [26]
Fatima et al. [27]
g. 13457_13458delCT Codon deletion Leu-Gly Pakistani Yes 1 Fatima et al. [27]
g. 13139C>T Nonsense Gln-STOP Indian Yes 1 Thakur et al. [28]
Table 2 Characteristics of  the p. N103K homozygous sub-
ject
Trait Observed value
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treatment with recombinant leptin. The p. N103K muta-
tion was previously reported in Egyptian child, however 
its presence in Pakistani group, even at very low fre-
quency, indicates that this mutation can play important 
role in the development of morbid severe early-onset 
obesity.
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